

Gibson Dunn Advises Shareholders in Connection with Sale of Aicuris to Asahi Kasei

Firm News | February 27, 2026

Gibson Dunn advised the shareholders in connection with the sale of Aicuris Anti-infective Cures AG to Asahi Kasei, through its subsidiary Veloxis Pharmaceuticals, Inc. The acquisition price amounts to 780 million euros (approximately \$920 million USD).

Gibson Dunn regularly advises shareholders and life sciences companies on complex cross-border M&A transactions in the pharmaceutical sector.

The Gibson Dunn M&A team was led by Dr. Dirk Oberbracht and Sonja Ruttmann and included Ryan Murr, Dr. Aliresa Fatemi, Simon Stöhlker, Andreas Rief, Tim Windfelder, and David Lübke-meier. Dr. Lars Petersen, Kai Gesing, and Yannick Oberacker advised on regulatory and antitrust. Sean Feller advised on tax. Dr. Peter Gumnior advised on labor law aspects.

Related People

[Dirk Oberbracht](#)

[Sonja Ruttmann](#)

[Ryan A. Murr](#)

[Aliresa Fatemi](#)

[Simon Stöhlker](#)

[Andreas Rief](#)

[Tim Windfelder](#)

[David Lübke-meier](#)

[Lars Petersen](#)

[Kai Gesing](#)

[Yannick Oberacker](#)

[Sean C. Feller](#)

[Peter Gumnior](#)

Related Capabilities

[Mergers and Acquisitions](#)

[Private Equity](#)

[Private Company M&A Disputes](#)

[Life Sciences](#)

[Antitrust and Competition](#)

[Tax](#)

[Labor and Employment](#)